Donald Weaver is both a practicing medicinal chemist and clinical neurologist. He obtained his MD from Queen’s University, Canada and later completed a residency in clinical neurology (Dalhousie University, Canada) with a focus on behavioural neurology. After his MD training, he completed a PhD in chemistry (Queen’s University, Canada). His PhD was awarded for organic chemistry with a focus on the applications of molecular orbital quantum mechanics calculations in identifying novel compounds which he then synthesized and evaluated as potential therapies for epilepsy.

Today, Dr. Weaver is Director and a Senior Scientist at the Krembil Research Institute at the University Health Network. He is a professor of Chemistry, Medicine and Pharmaceutical Science at the University of Toronto and a clinical neurologist at Toronto Western Hospital. Dr. Weaver is also a Tier 1 Canada Research Chair, Chief Medical Officer of Treventis Corporation, and is the former President of Epilepsy Canada.

• Director and Senior Scientist, Krembil Research Institute, University Health Network (UHN), Toronto
• Research Director and Institute Co-Director, Krembil Brain Institute, University Health Network (UHN), Toronto
• Canada Research Chair, Tier 1, Division of Neurology, Department of Medicine, Faculty of Medicine, University of Toronto
• Professor, Department of Medicine (Neurology), Faculty of Medicine, University of Toronto
• Professor, Department of Chemistry, Faculty of Arts & Science, University of Toronto
• Professor, Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto
• Attending Neurologist: Toronto Western Hospital, University Health Network
• Founder & Chief Medical Officer, Treventis Corporation
• Chair, Clinical Research Core Committee, Toronto Dementia Research Alliance (TDRA)